Release Date: November 02, 2023
Expiration Date: November 02, 2024

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Watch this engaging program on the evolving role of asparaginase therapies in acute lymphocytic leukemia (ALL) and lymphoblastic lymphoma (LBL). Developed specifically for oncology nurses who care for adolescent, young adult, and adult patients, this program will highlight best practices in asparaginase therapy and strategies for monitoring for adverse events such as hypersensitivity reactions and silent inactivation.

Target Audience

This activity is designed for oncology nurses who provide care for pediatric, adolescent and young adult (AYA) patients, and adult patients with ALL/LBL.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Summarize current guidelines on the use of asparaginase-containing treatment regimens in adolescents, young adults, and adults with ALL and LBL
• Implement strategies for managing hypersensitivity reactions in patients with ALL and LBL including the use of serum asparaginase activity (SAA) levels
• Educate patients and families on the importance of prompt identification and management of hypersensitivity reactions

Agenda

Nursing Insights on the Management of Patients with ALL/LBL Treated with Asparaginase Therapy – Sandra Kurtin, PhD, ANP-C, AOCN, FAPO

Instructions for Participation and Credit

This activity is eligible for credit through November 2, 2024. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biography

Sandra Kurtin, PhD, ANP-C, AOCN, FAPO
Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona College of Medicine
Director of Advanced Practice
Hematology/Oncology Nurse Practitioner
The University of Arizona Cancer Center
Tucson, Arizona

Dr. Sandra Kurtin received her BSN, MS in oncology nursing, post-graduate certification in geriatric and adult practice, and most recently, her PhD in nursing at the University of Arizona. She is an Assistant Professor of Clinical Medicine and Adjunct Clinical Assistant Professor of Nursing at The University of Arizona College of Medicine and is a Director of Advanced Practice and a Hematology/Oncology Nurse Practitioner at The University of Arizona Cancer Center.

Dr. Kurtin is a founding board member and president of the Advanced Practitioner Society for Hematology and Oncology (APSHO), as well as a member of American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Academy of Nurse Practitioners (AANP), and Oncology Nursing Society (ONS). In addition, she is a member of the executive committee, board of directors and co-chair of the Nursing Leadership Board for the MDS Foundation. Dr. Kurtin is associate editor for The Journal of the Advanced Practitioner in Oncology and is an editorial board member for JCO Clinical Cancer Informatics, ASH News, The Clinical Journal of Oncology Nursing, and the ASCO People Living with Cancer website. She has presented numerous regional, national, and international lectures on oncology related topics and has published numerous articles in peer-reviewed journals. Dr. Kurtin’s research focus is on heath technology engagement and communicative health literacy aimed at improving health self-management among older adult cancer survivors and their caregivers.

Accreditation

NURSING CREDIT MediCom Worldwide, Inc.is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 23-014-170

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosure

Dr. Sandra Kurtin, faculty for this educational activity, has relevant financial relationships related to consulting from AbbVie Inc., Agios, Inc., Amgen Inc., AstraZeneca, Bristol Myers Squibb Company, GlaxoSmithKline plc, and Takeda Oncology.

All of the relevant financial relationships listed for this individual have been mitigated.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee Disclosures

Joan Meyer, RN, MHA, Executive Director, and Cassie Rametta, Senior Program Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer Disclosure

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected].

Provided by MediCom Worldwide, Inc.
This activity is supported by an independent medical education grant from Jazz Pharmaceuticals.

©2023 MediCom Worldwide, Inc., 4607 Library Rd., Ste. 220 #2001 · Bethel Park, PA 15102, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.